Heart attacks and stroke: The risk of DPP-4 anti-diabetes drugs

Last Updated on

May 06, 2018 – In April 2016 the American Food and Drug Administration (FDA) took regulatory action by mandating label changes with new warnings about an increased risk of heart failure for  new diabetes medicines in the dipeptidyl peptidase-4 (DPP-4) inhibitor drug class, including Saxagliptin (Onglyza), Saxaglitin/Metformin (Kombiglyze XR), Alogliptin (Nesina), Alogliptin/Metformin (Kazano), Alogliptin/Pioglitazone (Oseni), and  Dapagliflozin/Saxagliptin (Qtern).

Stroke victim.

New research, which has been published on  April 14, 2018 in the Journal Pharmacoepidemiology & Drug Safety, entitled “Cardiovascular safety signals with dipeptidyl peptidase‐4 inhibitors: A disproportionality analysis among high‐risk patients” has investigated heart-related side effects reports submitted to the FDA Adverse Event Reporting System (FAERS) from 2006 to 2015.

When concentrating this Postmarketing surveillance on the DPP‐4 class of anti-diabetes medicines, increased reporting of major adverse cardiac events (MACE)] were noted. In particular, signals of disproportional reporting (SDR) emerged for heart failure with drugs containing linagliptin (e.g., Linagliptin (Tradjenta), Linagliptin/Metformin (Jentadueto), Linagliptin/Empagliflozin (Glyxambi)), and saxagliptin (e.g., Saxagliptin (Onglyza), Saxagliptin/Metformin (Kombiglyze XR), and Dapagliflozin/Saxagliptin (Qtern)), for myocardial infarction with drugs containing alogliptin [e.g., Alogliptin (Nesina), Alogliptin/Metformin (Kazano), and Alogliptin/Pioglitazone (Oseni)), and for cerebral infarction with sitagliptin [e.g., Sitagliptin (Januvia), Sitagliptin/Metformin (Janumet), Sitagliptin (Juvisync), and Sitagliptin/Ertugliflozin (Steglujan)).

The collective evidence from these analyses would strongly suggest that drug label warnings about heart failure which were mandated by the FDA for certain DPP-4 diabetes drugs back in 2016 urgently need differential updating and strengthening in order to adequately inform physicians and patients alike about the potentially fatal risks  associated with some DPP-4 class medications.

Thus, a more precise and stronger warning for myocardial infarction (heart attack) would be justified for Alogliptin (Nesina), Alogliptin/Metformin (Kazano), and Alogliptin/Pioglitazone (Oseni)). Likewise, a more precise and stronger warning for cerebral infarction (stroke) would be justified for Sitagliptin (Januvia), Sitagliptin/Metformin (Janumet), Sitagliptin (Juvisync), and Sitagliptin/Ertugliflozin (Steglujan). Hopefully, FDA will act swiftly upon.

Gliptines, inhibitors of dipeptidyl peptidase 4 (DPP-4),  are a class of oral hypoglycemics that block DPP-4. They are be used to treat diabetes mellitus type 2. Glucagon increases blood glucose levels, and DPP-4 inhibitors reduce glucagon and blood glucose levels. The mechanism of DPP-4 inhibitors is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.

Print Friendly, PDF & Email

Tags: , , , , , , , , , , , , , , , ,
About the Author
thassodotcom Ph.D.; Professor in Pharmacology and Toxicology. Senior expert in theragenomic and personalized medicine and individualized drug safety. Senior expert in pharmaco- and toxicogenetics. Senior expert in human safety of drugs, chemicals, environmental pollutants, and dietary ingredients.

Your opinion


No comments yet

thasso: conditions

thasso: tweets

thasso post: magazine

View my Flipboard Magazine.

thasso: categories

thasso: archives

thasso: simple chat

You must be a registered user to participate in this chat.

  • When macrophages are deprived of oxygen May 24, 2019
    Infected tissue has a low concentration of oxygen. The body's standard immune mechanisms, which rely on oxygen, can then only function to a limited extent. How does the immune system nevertheless manage to control bacteria under such conditions? Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Regensburg discovered that fewer metabolites are produced in the citric […]
  • Science Snapshots -- May 2019 May 24, 2019
    Researchers at Berkeley Lab's Molecular Foundry have predicted fascinating new properties of lithium; a powerful combination of experiment and theory has revealed atomic-level details about how silver helps transform carbon dioxide gas into a reusable form; new study reports the first comprehensive, highly coordinated effort to examine the global diversity and biogeography of activated sludge […]
  • Information and language in news impact prejudice against minorities May 23, 2019
    Researchers at the Institute of Psychology show how news about immigrants and language describing immigrants shape prejudice against immigrants and other social minorities, as part of the project 'Immigrants in the Media.' For instance, nouns used for describing the ethnicity of immigrants enhance prejudice against immigrants more than adjectives.
  • Artificial atomic scale materials: Discovering how electrons fatten! May 23, 2019
    A single and isolated electron has a clear electrical charge, magnetic moment and mass, and its free movement can be precisely predicted. Spanish scientists fabricated a nanoscale artificial material manipulating atoms one after the other and discovered that electrons around are very heavier. Heavy electrons are promising particles which endow of new functionalities to novel […]
  • Allogeneic stem cell transplantation in non-Hodgkin lymphoma: benefit remains unclear May 23, 2019
    Meaningful studies are lacking for certain patient groups. Disease-specific registries could help close the data gap.